Understanding differences in BCG vaccine effectiveness against tuberculosis
Molecular basis of BCG vaccine sub-strain heterogeneity
['FUNDING_R01'] · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · NIH-11028107
This study is looking at how different versions of the BCG vaccine for tuberculosis work in people and animals, hoping to find ways to make the vaccine more effective for everyone.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR (nih funded) |
| Locations | 1 site (COLLEGE STATION, UNITED STATES) |
| Trial ID | NIH-11028107 on ClinicalTrials.gov |
What this research studies
This research investigates the varying effectiveness of the BCG vaccine against tuberculosis (TB) by examining different sub-strains produced in various countries. It aims to understand how these differences affect the immune response in humans and animal models. By analyzing the molecular and epigenetic factors that contribute to vaccine efficacy, the study seeks to improve current TB vaccination strategies. Patients may benefit from insights that could lead to more effective vaccines in the future.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have received the BCG vaccine and are at risk of tuberculosis infection.
Not a fit: Patients who have not received the BCG vaccine or those with conditions that prevent them from participating in vaccine trials may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective TB vaccines, improving protection for individuals at risk.
How similar studies have performed: Previous research has shown that understanding the molecular basis of vaccine efficacy can lead to significant advancements in vaccine development.
Where this research is happening
COLLEGE STATION, UNITED STATES
- TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR — COLLEGE STATION, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CIRILLO, JEFFREY D. — TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR
- Study coordinator: CIRILLO, JEFFREY D.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.